Skip to main content
2114 search results for:

COMT Inhibitor 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-03-2022 | Pityriasis Lichenoides Chronica | ReviewPaper

    COMT Inhibitors in the Management of Parkinson’s Disease

    Levodopa treatment remains the gold standard for Parkinson’s disease, but shortcomings related to the pharmacological profile, notably, oral administration and the consequent occurrence of motor complications, have led to the development of …

  2. 01-04-2019 | ReviewPaper

    Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease

    MAO-B and COMT are both enzymes involved in dopamine breakdown and metabolism. Inhibitors of these enzymes are used in the treatment of Parkinson’s disease. This review article describes the scientific background to the localization and function …

  3. 01-04-2000 | OriginalPaper

    Can COMT Inhibitors Improve Cognitive Functions in Patients with Parkinson’s Disease?

    Catechol-O-methyltransferase (COMT) inhibitors are used in patients with Parkinson’s disease to reduce the complications associated with long term levodopa therapy. By inhibiting catecholamine catabolism, they extend the pharmacological effects of …

  4. 01-06-2000 | ReviewPaper

    Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

    When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible …

  5. 01-07-2003 | OriginalPaper

    Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans

    Objective: To determine the tolerability, pharmacodynamics and pharmacokinetics of single oral doses of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, in healthy male volunteers. Methods: Single increasing oral doses of BIA …

  6. 01-10-2003 | OriginalPaper

    Optimizing levodopa pharmacokinetics in Parkinson’s disease: the role of COMT inhibitor

  7. 01-11-2002 | OriginalPaper

    Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects

    The toxicity profiles of entacapone and tolcapone, novel catechol-O-methyl-transferase (COMT) inhibitors, have been reported to differ from each other. It has also been shown that tolcapone, but not entacapone, is a potent uncoupler of oxidative …

  8. 01-09-2005 | OriginalPaper

    The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats

    Levodopa treatment has been shown to increase plasma homocysteine levels in Parkinson’s disease (PD) patients and this may lead to an increased risk for coronary arterial diseases. Levodopa is metabolised via O-methylation by …

  9. 01-01-1997 | OriginalPaper

    Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism

    Inhibitors of the enzyme catechol-O-methyl transferase (COMT) may be useful adjuncts to L-DOPA in the treatment of Parkinson's disease as they offer the possibility of increasing the availability of the amino acid. It is unknown whether a COMT

  10. 01-01-2002 | OriginalPaper

    Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys

    Parkinson's disease (PD) is characterised by a loss of pigmented dopaminergic neurones in the zona compacta of substantia nigra. The mechanisms underlying nigral cell death remain unknown but may involve oxidative damage. There has been concern …

  11. Open Access 29-05-2024 | Entacapone | Online First

    The Catechol O-Methyltransferase Inhibitor Entacapone in the Treatment of Parkinson’s Disease: Personal Reflections on a First-in-Class Drug Development Programme 40 Years On

    In the 1980s, Orion Pharma, then a mid-ranking Nordic area pharmaceutical company, established a drug development programme on the inhibition of catechol O-methyltransferase (COMT). This enzyme, which plays an important role in the inactivation of …

  12. 14-05-2024 | Levodopa | Online First

    Sublingual apomorphine in the treatment of Parkinson’s disease

    Advanced Parkinson´s disease (PD) is often complicated by fluctuations of disability depending on plasma levels of levodopa. For most patients OFF phases with worsening of tremor and immobility, but also pain, depression, autonomic symptoms are …

  13. Open Access 11-04-2024 | Parkinson's Disease | Online First

    Parkinson's disease and vitamins: a focus on vitamin B12

    Parkinson’s disease (PD) has been linked to a vast array of vitamins among which vitamin B12 (Vit B12) is the most relevant and often investigated specially in the context of intrajejunal levodopa infusion therapy. Vit B12 deficiency, itself, has …

  14. 01-06-2024 | Amyotrophic Lateral Sclerosis | OriginalPaper

    Aberrant CHCHD2-associated mitochondriopathy in Kii ALS/PDC astrocytes

    Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex (ALS/PDC), a rare and complex neurological disorder, is predominantly observed in the Western Pacific islands, including regions of Japan, Guam, and Papua. This enigmatic condition …

  15. Open Access 19-03-2024 | Stroke | ReviewPaper

    Genetics of ischemic stroke functional outcome

    Ischemic stroke, which accounts for 87% of cerebrovascular accidents, is responsible for massive global burden both in terms of economic cost and personal hardship. Many stroke survivors face long-term disability—a phenotype associated with an …

  16. 17-04-2024 | Parkinson's Disease | News | Article

    Better motor control with subcutaneous levodopa–carbidopa

    The patients underwent an open-label run-in phase to switch their current oral levodopa treatment regimens, including catechol- O- methyltransferase (COMT) inhibitors, to equivalent doses of immediate-release oral levodopa–carbidopa that were optimized over 4–6 weeks.

  17. Open Access 03-04-2024 | Parkinson's Disease | OriginalPaper

    The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications

    The concept of a ‘microbiota-gut-brain axis’ has recently emerged as an important player in the pathophysiology of Parkinson disease (PD), not least because of the reciprocal interaction between gut bacteria and medications. The gut microbiota can …

  18. Open Access 01-03-2022 | Pharmacodynamics | OriginalPaper

    Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

    For decades, levodopa ( l -DOPA) has remained the gold standard in treating Parkinson’s disease, a progressive neurodegenerative disease characterized by a deficiency of neurotransmitters, especially dopamine [ 1 – 3 ]. l -DOPA is often used in …

  19. Open Access 10-04-2023 | Parkinson's Disease | OriginalPaper

    The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone

    Opicapone is a long-acting, third generation selective catechol‐o‐methyl transferase (COMT) inhibitor, which became available in Europe in 2016 and is indicated as adjunctive treatment to levodopa in people with Parkinson's disease (PwP) who …

  20. 23-02-2024 | Parkinson's Disease | Online First

    Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms

    A prominent neurodegenerative ailment called Parkinson’s disease (PD) is characterized by a demise of dopaminergic neurons in the substantia nigra pars compacta (SNPs). Tremors, stiffness, and cognitive deficits are just a few of the symptoms that …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.